Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aliskiren
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Mallinckrodt Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Mallinckrodt and Endo Announce Significant Progress in Proposed Merger
Details : Under the merger agreement, the combined generic businesses & Endo's injectables business will form a new standalone entity, which includes Tekturna-Generic (aliskiren hemifumarate) for hypertension.
Product Name : Tekturna-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 13, 2025
Lead Product(s) : Aliskiren
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Mallinckrodt Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger